Michael Beck
Mainz, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Emerging drugs for lysosomal storage diseases.
Journal: Expert opinion on emerging drugs
Published: June 19, 2010
Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
Journal: Current pharmaceutical biotechnology
Published: June 15, 2010
Villa Metabolica - a center of excellence for the diagnosis and treatment of lysosomal storage disorders.
Journal: Wiener medizinische Wochenschrift (1946)
Published: May 03, 2010
LSDs and the immune system.
Journal: International journal of clinical pharmacology and therapeutics
Published: December 31, 2009
Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety.
Journal: Expert opinion on biological therapy
Published: February 25, 2009
Update on mucopolysaccharidosis type II.
Journal: Acta paediatrica (Oslo, Norway : 1992)
Published: March 30, 2007
The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease.
Journal: Acta paediatrica (Oslo, Norway : 1992). Supplement
Published: May 25, 2006
Assessing multiorgan disease severity: scoring systems and applicability in LSDs.
Journal: Acta paediatrica (Oslo, Norway : 1992). Supplement
Published: May 25, 2006
Fabry disease: overall effects of agalsidase alfa treatment.
Journal: European journal of clinical investigation
Published: December 21, 2004
Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.
Journal: Expert opinion on investigational drugs
Published: May 31, 2002
Last Updated: 09/26/2026